Revvityブログ
発見から治療までのイノベーションを促進
 
     
    
            
        Latest
      
    
    Optimizing functional genomics research tools by aligning their design with the ongoing evolution of the genome.
Functional Genomic Screening 
October 30, 2025  -  3  min read
       
      Physiological Model Solutions, Cancer
        Why you should use 3D cell models for high throughput screening.
            October 24, 2024 -
            4 min read
          
          
         
      Clinical Genomics
        Ultra-rapid whole genome sequencing: helping to revolutionize NICU care and end diagnostic odysseys.
            October 23, 2024 -
            4 min read
          
          
         
      NGS, Cancer, Biomarker Detection
        Why are miRNAs promising non-invasive Biomarkers?
            October 23, 2024 -
            5 min read
          
          
         
      Small Molecule Drug Discovery
        How to address the bottlenecks in AAV manufacturing.
            October 21, 2024 -
            3 min read
          
          
         
      NGS
        Navigating the complexities of miRNA sequencing data analysis.
            October 11, 2024 -
            3 min read
          
          
         
       
      Disease Research
        Ultrasensitive α-Synuclein detection and quantification using immunoassays.
            October 9, 2024 -
            2 min read
          
          
         
      Cell and Gene Therapy
        BOOSTing lentiviral transduction for T cell therapy success.
            October 7, 2024 -
            2 min read
          
          
         
      NGS
        Leveraging small RNA-Seq library preparation for ribosome profiling (ribo-seq).
            October 2, 2024 -
            3 min read
          
          
         
      Reproductive Health
        The importance of newborn screening software: enhancing efficiency, accuracy, and patient care.
            October 1, 2024 -
            7 min read
          
          
         
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                  